CCR5 and neoplasm: IL-6/JAK–STAT3 inhibitors, IL-1 blockers, and strategies targeting CCR2/CCR5 are under investigation in oncology and may, with careful selection, have dual relevance in patients with prior severe COVID-19 and inflammation-dominated tumor microenvironments [68,139,147,148,149,150,158].